within Pharmacolibrary.Drugs.ATC.L;

model L01XX10
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX10</td></tr><td>route:</td><td></td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Masoprocol (also known as nordihydroguaiaretic acid, NDGA) is a synthetic antineoplastic agent with cytostatic and antioxidant properties. It was previously explored for the treatment of malignant melanoma and as a topical agent, but is not currently approved for clinical use.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters for masoprocol in humans are reported in published literature.</p><h4>References</h4><ol><li><p>Al-Shuhaib, MBS, et al., &amp; Al-Shuhaib, JMB (2024). Masoprocol: a promising candidate for targeting insulin resistance by inhibiting resistin with optimal druglikeness Potentials: an . <i>Journal of biomolecular structure &amp; dynamics</i> 42(19) 10044–10056. DOI:<a href=\"https://doi.org/10.1080/07391102.2023.2254842\">10.1080/07391102.2023.2254842</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37671847/\">https://pubmed.ncbi.nlm.nih.gov/37671847</a></p></li><li><p>Lü, JM, et al., &amp; Chen, C (2010). Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. <i>Medical science monitor : international medical journal of experimental and clinical research</i> 16(5) RA93–RA100. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20424564/\">https://pubmed.ncbi.nlm.nih.gov/20424564</a></p></li><li><p>Anders, NM, et al., &amp; Rudek, MA (2022). Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of pharmaceutical and biomedical analysis</i> 209 114525–None. DOI:<a href=\"https://doi.org/10.1016/j.jpba.2021.114525\">10.1016/j.jpba.2021.114525</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34906921/\">https://pubmed.ncbi.nlm.nih.gov/34906921</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX10;
